ArticleWorld journal of urology2026
Years of life lost from metastatic prostate cancer according to household income.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionYears of life lost (YLL) from metastatic prostate cancer (mPCa) according to household income, relative to population controls, have not been quantified.
methodsWithin the Surveillance, Epidemiology, and End Results (SEER) database (2004-2021), mPCa patients aged 40-80 years were identified and stratified between low vs. high household income based on the median distribution. For each patient, an age- and sex-matched control was generated from Social Security Administration life tables using Monte Carlo simulation. YLL of low vs. high income mPCa patients were quantified relative to simulated controls, until the age of 80 years, using Kaplan-Meier methodology. Subsequently, multivariable competing risks regression (CRR) models were fitted.
resultsOverall, 37,094 mPCa patients were included. The median household income ranged from $75k to $80k/year, with 20,004 (53.9%) low vs. 17,090 (46.1%) high income mPCa patients. YLL values were 7.7 in low vs. 5.9 in high income mPCa patients (Δ: 1.8). In sensitivity analyses among metastatic substages, YLL values were as follows: 6.2 vs. 4.7 (Δ: 1.5) in M1a, 7.5 vs. 5.6 (Δ: 1.9) in M1b, 8.9 vs. 7.3 (Δ: 1.6) in M1c, in low vs. high income mPCa patients, respectively. In multivariable CRR models, household income independently predicted 1.1-fold higher cancer-specific mortality (CSM, multivariable hazard ratio [mHR] 1.14; p < 0.001). In sensitivity analyses stratified by metastatic substage, mHRs for CSM were as follows: 1.22 (p < 0.001) in M1a, 1.14 (p < 0.001) in M1b, 1.11 in M1c (p < 0.001).
conclusionLow household income is associated with less favorable overall survival and higher CSM in mPCa patients. In consequence, measures aimed at reducing or ideally eliminating these survival disadvantages should be implemented.
Indexed as
Identifiers
42250108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.